April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Meganuclease Targeting Herpes Simplex Virus type I protects Against Viral Endothelitis: an organ culture model
Author Affiliations & Notes
  • Benoit Chapellier, Jr.
    Inserm 968, institut de la vision, paris, France
  • Marc Labetoulle
    Ophthalmology, Center Hosp Univ Bicetre, Le Kremlin Bicetre, France
  • Sylvain Arnould
    Cellectis Therapeutics SAS, Romainville, France
  • Stephanie Grosse
    Cellectis Therapeutics SAS, Romainville, France
  • Julianne Smith
    Cellectis Therapeutics SAS, Romainville, France
  • Jose A. Sahel
    UMR-S 968, Institut de la Vision, Paris, France
  • Eric E. Gabison
    Hopital Bichat AP-HP Cornea, Fondation A de Rothschild, Paris, France
  • Footnotes
    Commercial Relationships  Benoit Chapellier, Jr., None; Marc Labetoulle, None; Sylvain Arnould, Cellectis Therapeutics SAS (E); Stephanie Grosse, Cellectis Therapeutics SAS (E); Julianne Smith, Cellectis Therapeutics SAS (E); Jose A. Sahel, None; Eric E. Gabison, None
  • Footnotes
    Support  OSEO Active Grant
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6655. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benoit Chapellier, Jr., Marc Labetoulle, Sylvain Arnould, Stephanie Grosse, Julianne Smith, Jose A. Sahel, Eric E. Gabison; Meganuclease Targeting Herpes Simplex Virus type I protects Against Viral Endothelitis: an organ culture model. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6655.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Herpetic Keratitis is a leading cause of decreased best corrected visual acuity in developed and developing countries. Despite advances in antiviral therapies, past history of HSV keratitis is associated with poor prognosis of subsequent penetrating keratoplasty (PK). HSV infection of the grafted cornea is highly prevalent in primary graft failure following PK, furthermore HSV recurrence may favor secondary graft rejection. The aim of this study is to assess the antiviral property of a meganuclease targeting HSV in the prevention of HSV endothelitis.

Methods: : Normal rabbit corneas were placed in organ culture using an immersion method and transduced by a recombinant adeno-associated virus (rAAV) allowing constitutive expression of meganucleases targeting HSV-1 genome or containing the same expression cassette with a non-coding sequence. These organs were then submitted to infection by recombinant HSV-1 F(1) virus equipped with a LacZ expressing cassette at M.O.I. 0.001 to 0.1% in liquid or semi-solid medium. Infection rates for plaques or cells in endothelium were established by immunostaining of envelope protein gD or X-gal staining after the end of first or second lytic cycle.

Results: : Meganuclease targeting the ICP0 gene which encodes an E3 ubiquitin ligase involved in viral reactivation and replication did not change infection rates in the present organ culture model, but reduced the average size of plaques in endothelium with a decrease of 27-46%. Conversely, the meganuclease directed against the major capsid protein UL19 lowered the number and size of plaques, both being reduced by half at M.O.I. 0.001%. Consequently, the expression of a meganuclease in endothelium, evidenced by RT-PCR, could either reduce infectious particle production or induce cell resistance to HSV-1.

Conclusions: : These meganucleases are currently checked for their anti-infective properties in an in vivo model of endothelitis.Our organ culture model of herpetic endothelial infection is reproducible and efficient to quantify viral proliferative capacity. Meganuclease transduction confers a significant inhibition of viral pathogenic effect. Meganuclease gene therapy targeting HSV-1 DNA may be an effective treatment to protect against HSV endothelitis following PK.

Keywords: cornea: endothelium • herpes simplex virus • transplantation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.